C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 405/00 (2006.01) A61K 31/557 (2006.01) A61K 47/40 (2006.01)
Patent
CA 2336952
The present invention relates to 5-thia- .omega. -substituted phenyl--prostaglandin E derivatives of the formula (I) (see formula I) (wherein, all the symbols are as defined in the specification), process for producing them and pharmaceutical compositions comprising them as active ingredient. The compounds of the formula (I) can bind to PGE2 receptors (especially, subtype EP4) strongly, so they are expected to be useful for prevention and/or treatment of immunological diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjoegren's syndrome, chronic rheumarthrosis and systemic lupus erythematosus etc., and rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia, systemic inflammatory response syndrome, ambustion pain, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, and shock etc. Further, it is thought that EP4 subtype receptor relates to sleeping disorder and blood platelet aggregation, so the compounds of the present invention are expected to be useful for the prevention and/or treatment of such diseases.
L'invention concerne des dérivés de phényl-postaglandine E 5-thia- omega -substitués de la formule générale (I) dans laquelle chaque symbole est tel que défini dans le mémorandum descriptif. Du fait de sa capacité de se lier fortement aux récepteurs de PEG2 (en particulier le sous-type EP4), les composés de formule générale (I) sont utiles pour la prévention et/ou le traitement de maladies immunologiques, de l'asthme, de la dysplasie osseuse, de la mort des cellules nerveuses, de l'insuffisance respiratoire, de l'hépatopathie, de l'hépatite aiguë, de la néphrite, de l'insuffisance rénale, de l'hypertension, de l'ischémie myocardique, du syndrome inflammatoire systémique, des douleurs d'échaudage, du choc septique, du syndrome hémophagique, du syndrome de l'activation des macrophages, de la maladie de Still, de la maladie de Kawasaki, des brûlures, de la granulomatose systémique, de la colite ulcéreuse, de la maladie de Crohn, de l'hypercytokinémie à la dialyse, des déficiences polyviscérales, de l'état de choc, etc. De plus, ces composés peuvent intervenir dans la lutte contre les troubles du sommeil et l'agrégation plaquettaire, et sont donc utiles pour la prévention ou le traitement desdites maladies.
Maruyama Toru
Ohuchida Shuichi
Mccarthy Tetrault Llp
Ono Pharmaceutical Co. Ltd.
LandOfFree
5-thia-.omega.-substituted phenyl-prostaglandin e... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-thia-.omega.-substituted phenyl-prostaglandin e..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-thia-.omega.-substituted phenyl-prostaglandin e... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2022071